BreezeBio
This Scientist I role on GenEdit’s Immunology team focuses on advancing genetic medicines for immune-based diseases using the company’s hydrophilic nanoparticle (HNP) delivery technology. The scientist will help shape and execute R&D strategy for immune programs, contributing to program design and candidate selection for tissue- and cell-specific nucleic acid delivery. The position operates in a highly collaborative, interdisciplinary biotech environment spanning chemistry, formulation, screening, and preclinical groups. The role is based in South San Francisco/Brisbane, CA, within a rapidly growing gene therapy-focused company.
Headquarters
Brisbane, California, United States
Company Size
11-50 employees
Founded
2016
BreezeBio (formerly GenEdit) is a biotechnology company focused on precision delivery of genetic medicines to treat autoimmune diseases and oncology. Powered by its NanoGalaxy® programmable nanoparticle delivery platform, BreezeBio targets specific immune cells to restore immune balance and achieve durable cures, with a lead program (BRZ-101) in Type 1 Diabetes. The company advances an internal pipeline of immune-modulating therapies and collaborates with biopharma partners including Genentech and Sarepta Therapeutics.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BreezeBio.
BreezeBio didn’t post a salary, so this is our estimate from similar listings.